If as a holding company, AMBS is not intent on selling selling or spinning-off LymPro in the near future, as has been mentioned numerpous times by GC himself, then where are they going to obtain the cash to bring ESS, Eltro, and MANF's 11 off spring to evetual market - or some acceptable milestone for either a sale, multiple licensing streams or JV Partnership? Will you wait to see how you fare when the next 1-Bil. is diluted into the float?

Would not a JV or series of licensings be prudent to allow for revenue recognition and create intrinsic value for both the company and build greater shareholder value?

Quote:

---

"The Company expects to commercialize LymPro in the second half of 2014 under CLIA in Alzheimer’s disease, one of the largest and most underserved markets in the world ($200B+ in the US alone, $500B+ worldwide) where we will seek to fulfill the key unmet medical need of early diagnosis. While CLIA will not allow the Company to generate the revenues that a full FDA approval eventually will, we believe there is an opportunity to generate meaningful revenues that will offset development costs in other areas until such a point where we are able to realize revenue generation in other categories..."

---

See more at: http://www.thechairmansblog.com/amarantus-bio...0SuG3.dpuf